BridgeBio Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Oncology (BBOT).

Price Target Range — 6 Quarters

Analyst Consensus — 9 Analysts

9Buy

Consensus RatingOutperform# Analysts9Avg. Consensus PT$21Upside to Avg. PT+709.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Morgan Stanley	Sean Laaman	PT Cut	Overweight	$18→$13
Oct 20, 2026	Oppenheimer	Mazahir Alimohamed	PT Cut	Outperform	$22→$16
Sep 11, 2026	JP Morgan	Priyanka Grover	PT Cut	Overweight	$25→$23
Sep 10, 2026	Leerink Partners	Andrew Berens	PT Cut	Outperform	$39→$27
Sep 9, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$23→$20
Sep 9, 2026	Raymond James	Sean McCutcheon	PT Cut	Outperform	$24→$22
Sep 9, 2026	Stifel	Laura Prendergast	PT Cut	Buy	$23→$15
Sep 9, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$25
Aug 14, 2026	JP Morgan	Priyanka Grover	PT Cut	Overweight	$27→$25
Jul 8, 2026	JP Morgan	Priyanka Grover	Initiate	Overweight	$27
Jun 22, 2026	Oppenheimer	Mazahir Alimohamed	Assumes	Outperform	$22
May 11, 2026	Canaccord Genuity	John Newman	Initiate	Buy	$23
Mar 6, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$27→$29
Feb 11, 2026	Stifel	Laura Prendergast	Initiate	Buy	$23
Jan 9, 2026	Raymond James	Sean McCutcheon	Initiate	Outperform	$24
Dec 11, 2025	Wedbush	David Nierengarten	Maintained	Outperform	$25
Dec 5, 2025	Morgan Stanley	Sean Laaman	Initiate	Overweight	$20
Nov 25, 2025	Wedbush	David Nierengarten	Maintained	Outperform	$25
Nov 13, 2025	Oppenheimer	Matthew Biegler	PT Cut	Outperform	$23→$22
Sep 17, 2025	Leerink Partners	Andrew Berens	Initiate	Outperform	$25

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.

Benzinga Newsdesk

BridgeBio Oncology Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

BridgeBio Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

PRO
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

PRO
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

PRO
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

PRO
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

PRO
Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

People Also Watch

People Also Watch

BridgeBio Oncology Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

BridgeBio Oncology Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

PROOppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

PROLeerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

PROCanaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

PRORaymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

PROStifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

PRO
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

PRO
Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

PRO
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

PRO
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

PRO
Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15